ABOS - Acumen Pharmaceuticals, Inc.

0.9742
-0.076   -7.781%

Share volume: 193,040
Last Updated: 04-08-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.07%

PREVIOUS CLOSE
CHG
CHG%
$1.05
-0.08
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 0%
Dept financing 4%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.38%
1 Month
-18.82%
3 Months
-40.96%
6 Months
-57.46%
1 Year
-74.63%
2 Year
-74.56%
Key data
Stock price
$0.97
P/E Ratio 
0.00
DAY RANGE
$0.96 - $1.11
EPS 
-$1.71
52 WEEK RANGE
$0.90 - $3.93
52 WEEK CHANGE
-$73.74
MARKET CAP 
103.337 M
YIELD 
N/A
SHARES OUTSTANDING 
60.080 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
3.01
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$300,484
AVERAGE 30 VOLUME 
$237,362
Company detail
CEO: Daniel J. O'Connell
Region: US
Website: acumenpharm.com
Employees: 20
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage.

Recent news
loading